
ALRN
Healthcare · Biotechnology · $45.7M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2024
EPS trend, 90 days to now · -9.1% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 4, 2024 | After the close | -0.41 | -0.27 | +34.1% |
| Aug 9, 2024 | After the close | -0.42 | -0.45 | -7.1% |
| May 15, 2024 | After the close | -0.14 | -0.86 | -514.3% |
| Feb 28, 2024 | Before the open | -0.16 | -1.54 | -862.5% |
| Oct 13, 2023 | After the close | — | -0.40 | — |
| Aug 11, 2023 | After the close | -0.52 | -0.39 | +25.0% |
| May 8, 2023 | Before the open | -0.86 | -1.05 | -22.1% |
| Mar 20, 2023 | After the close | -1.34 | -1.02 | +23.9% |
| Nov 1, 2022 | Before the open | -1.65 | -1.40 | +15.2% |
| Aug 15, 2022 | After the close | -1.80 | -1.80 | 0.0% |
| May 5, 2022 | After the close | -1.53 | -1.80 | -17.6% |
| Mar 28, 2022 | After the close | -1.60 | -1.60 | 0.0% |
| Nov 12, 2021 | Before the open | -1.40 | -1.40 |
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase…
| 0.0% |
| Aug 11, 2021 | After the close | -1.47 | -1.20 | +18.4% |
| May 11, 2021 | After the close | -1.07 | -1.60 | -49.5% |
| Mar 24, 2021 | After the close | -2.55 | -2.40 | +5.9% |
| Nov 12, 2020 | After the close | -2.96 | -2.60 | +12.2% |
| Aug 5, 2020 | After the close | -3.75 | -2.80 | +25.3% |
| May 11, 2020 | Before the open | -4.05 | -4.80 | -18.5% |
| Mar 30, 2020 | After the close | -5.45 | -5.20 | +4.6% |
| Nov 7, 2019 | Before the open | -4.75 | -5.60 | -17.9% |
| Aug 6, 2019 | After the close | -4.50 | -5.20 | -15.6% |
| May 8, 2019 | After the close | -6.65 | -9.80 | -47.4% |
| Mar 29, 2019 | Before the open | -10.35 | -9.60 | +7.2% |
| Nov 7, 2018 | After the close | -11.10 | -10.00 | +9.9% |
| Aug 7, 2018 | After the close | -10.65 | -11.20 | -5.2% |
| May 9, 2018 | After the close | -9.95 | -10.40 | -4.5% |